RxTrials Institute Drug Pipeline Alert

The randomized, placebo-controlled trial evaluated the safety and immunogenicity of different doses of the VLP (trivalent) vaccine in 300 healthy adults. The vaccine induced robust hemagglutination inhibition (HAI) responses, which have been shown to help protect against seasonal influenza, according to Novavax.

The adverse events that were reported from the trial were similar to those reported for other approved influenza vaccines, the company added. Adverse events such as fever, chills, joint pain, muscle aches, headaches and fatigue were reported at a higher frequency among vaccine recipients compared with placebo recipients.